Synergistic antiproliferative activity of suramin and α2A-interferon against human colorectal adenocarcinoma cell lines: In vitro studies

A. Falcone, R. Danesi, L. Zaccaro, D. Pieracci, E. Pfanner, C. Cianci, M. Andreuccetti, G. Malvaldi, M. Del Tacca, P. F. Conte

Research output: Contribution to journalArticlepeer-review

Abstract

Suramin, a polysulphonated naphthylurea proven to be an effective anticancer agent against selected tumours, and α2A-interferon (α2A-IFN) were investigated for their combined effects on HCT-8, HCT-15, CL-D, SW-480 and SW-620 human colorectal adenocarcinoma cell lines. All lines were sensitive to clinically achievable concentrations of suramin in a dose-dependent manner, while α2A-IFN alone induced only a modest reduction of cell growth. Concomitant treatment with suramin and α2A-IFN resulted in a synergistic inhibition of cell viability in each cell line at all doses tested. However, when suramin and α2A-IFN were administered sequentially, inhibition of cell viability was clearly dependent on the timing of treatment schedule, with maximum effect obtained when α2A-IFN was administered prior to suramin. In contrast, pretreatment with suramin was markedly inferior to the former one. In conclusion, suramin and α2A-IFN exert a synergistic effect on human colorectal cell proliferation in vitro at clinically achievable concentrations. This observation may have clinical relevance although the mechanisms of interaction remain to be elucidated.

Original languageEnglish
Pages (from-to)516-520
Number of pages5
JournalEuropean Journal of Cancer
Volume30
Issue number4
DOIs
Publication statusPublished - 1994

Keywords

  • cell lines
  • colorectal cancer
  • in vitro
  • suramin
  • α-interferon

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Synergistic antiproliferative activity of suramin and α2A-interferon against human colorectal adenocarcinoma cell lines: In vitro studies'. Together they form a unique fingerprint.

Cite this